Macrophage Heterogeneity in NASH: More Than Just Nomenclature.
作者信息
Parthasarathy Gopanandan, Malhi Harmeet
机构信息
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
出版信息
Hepatology. 2021 Jul;74(1):515-518. doi: 10.1002/hep.31790. Epub 2021 May 22.
Abstract
摘要
相似文献
1
Macrophage Heterogeneity in NASH: More Than Just Nomenclature.非酒精性脂肪性肝炎中的巨噬细胞异质性：不止于命名
Hepatology. 2021 Jul;74(1):515-518. doi: 10.1002/hep.31790. Epub 2021 May 22.
2
CD44 is a key player in non-alcoholic steatohepatitis.CD44 是非酒精性脂肪性肝炎的关键参与者。
J Hepatol. 2017 Aug;67(2):328-338. doi: 10.1016/j.jhep.2017.03.003. Epub 2017 Mar 16.
3
Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.髓系特异性 IRE1α 缺失可减少糖尿病非酒精性脂肪性肝炎诱导的肝癌小鼠模型中的肿瘤发生。
Metabolism. 2020 Jun;107:154220. doi: 10.1016/j.metabol.2020.154220. Epub 2020 Mar 31.
4
Not Chopped Liver-A Careful, Fate-Mapping Study of Macrophages in NASH.非肝切缘——非酒精性脂肪性肝炎中巨噬细胞的精细命运图谱研究。
Cell Metab. 2020 Sep 1;32(3):328-330. doi: 10.1016/j.cmet.2020.08.005.
5
Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2.脂联素-2 通过诱导 CXCR2 促进中性粒细胞-巨噬细胞串扰来介导非酒精性脂肪性肝炎。
J Hepatol. 2016 Nov;65(5):988-997. doi: 10.1016/j.jhep.2016.05.041. Epub 2016 Jun 4.
6
Pathophysiological mechanisms and therapeutic potentials of macrophages in non-alcoholic steatohepatitis.巨噬细胞在非酒精性脂肪性肝炎中的病理生理机制及治疗潜力
Expert Opin Ther Targets. 2016;20(5):615-26. doi: 10.1517/14728222.2016.1125883. Epub 2016 Jan 22.
7
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease.非酒精性脂肪性肝病中脂肪组织胰岛素抵抗与肝巨噬细胞的串扰。
J Hepatol. 2019 Nov;71(5):1012-1021. doi: 10.1016/j.jhep.2019.06.031. Epub 2019 Jul 10.
8
Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis.类胡萝卜素对非酒精性脂肪性肝病的新作用：巨噬细胞极化与肝脏稳态
Nutrients. 2016 Jun 24;8(7):391. doi: 10.3390/nu8070391.
9
Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor γ.和厚朴酚通过激活过氧化物酶体增殖物激活受体 γ 调节巨噬细胞极化来减轻饮食诱导的非酒精性脂肪性肝炎。
J Gastroenterol Hepatol. 2018 Feb;33(2):524-532. doi: 10.1111/jgh.13853.
10
The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.巨噬细胞活化标志物 sCD163 与非酒精性脂肪性肝病患者的形态学疾病分期相关。
Liver Int. 2016 Oct;36(10):1549-57. doi: 10.1111/liv.13150. Epub 2016 May 12.
引用本文的文献
1
Liver Sinusoidal Endothelial Cells in the Regulation of Immune Responses and Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.肝脏窦状内皮细胞在代谢功能障碍相关脂肪性肝病免疫反应和纤维化调节中的作用
Int J Mol Sci. 2025 Apr 23;26(9):3988. doi: 10.3390/ijms26093988.
2
Identification and validation of efferocytosis-related biomarkers for the diagnosis of metabolic dysfunction-associated steatohepatitis based on bioinformatics analysis and machine learning.基于生物信息学分析和机器学习的代谢相关脂肪性肝炎诊断中噬逝细胞相关生物标志物的鉴定和验证。
Front Immunol. 2024 Oct 21;15:1460431. doi: 10.3389/fimmu.2024.1460431. eCollection 2024.
3
Monocyte bioenergetics: An immunometabolic perspective in metabolic dysfunction-associated steatohepatitis.单核细胞生物能量学：代谢功能障碍相关脂肪性肝炎的免疫代谢观点。
Cell Rep Med. 2024 May 21;5(5):101564. doi: 10.1016/j.xcrm.2024.101564. Epub 2024 May 10.
4
Microbiome-liver crosstalk: A multihit therapeutic target for liver disease.微生物组-肝脏相互作用：肝脏疾病的多因素治疗靶点。
World J Gastroenterol. 2023 Mar 21;29(11):1651-1668. doi: 10.3748/wjg.v29.i11.1651.
5
Emerging targets for therapy in ALD: Lessons from NASH.ALD 治疗的新兴靶点：来自 NASH 的经验。
Hepatology. 2024 Jul 1;80(1):223-237. doi: 10.1097/HEP.0000000000000381. Epub 2023 Mar 21.
6
The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer-Challenges and opportunities.巨噬细胞在非酒精性脂肪性肝病和原发性肝癌中的矛盾作用——挑战与机遇
Front Mol Biosci. 2023 Feb 10;10:1129831. doi: 10.3389/fmolb.2023.1129831. eCollection 2023.
7
Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).非酒精性脂肪性肝病/脂肪性肝炎（NAFL/NASH）中的靶向治疗和新型信号通路。
Signal Transduct Target Ther. 2022 Aug 13;7(1):287. doi: 10.1038/s41392-022-01119-3.
8
MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH.miR-690 治疗可减少 NASH 中的纤维化和脂肪变性，并恢复特定的库普弗细胞功能。
Cell Metab. 2022 Jul 5;34(7):978-990.e4. doi: 10.1016/j.cmet.2022.05.008. Epub 2022 Jun 13.
9
Iron Metabolism and Immune Regulation.铁代谢与免疫调节。
Front Immunol. 2022 Mar 23;13:816282. doi: 10.3389/fimmu.2022.816282. eCollection 2022.
本文引用的文献
1
Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver.骨桥蛋白表达鉴定了肝脂肪变性中招募的巨噬细胞亚群，与枯否细胞不同。
Immunity. 2020 Sep 15;53(3):641-657.e14. doi: 10.1016/j.immuni.2020.08.004. Epub 2020 Sep 3.
2
Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid Overload during Non-alcoholic Steatohepatitis.枯否细胞自我更新受损改变了非酒精性脂肪性肝炎中肝脏对脂质过载的反应。
Immunity. 2020 Sep 15;53(3):627-640.e5. doi: 10.1016/j.immuni.2020.06.003. Epub 2020 Jun 19.
3
Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis.特定龛位的表观遗传景观重编程驱动非酒精性脂肪性肝炎中髓系细胞的多样性。
Immunity. 2020 Jun 16;52(6):1057-1074.e7. doi: 10.1016/j.immuni.2020.04.001. Epub 2020 May 1.
4
Resolving the fibrotic niche of human liver cirrhosis at single-cell level.解析人肝硬化的纤维性龛位于单细胞水平。
Nature. 2019 Nov;575(7783):512-518. doi: 10.1038/s41586-019-1631-3. Epub 2019 Oct 9.
5
Stellate Cells, Hepatocytes, and Endothelial Cells Imprint the Kupffer Cell Identity on Monocytes Colonizing the Liver Macrophage Niche.星状细胞、肝细胞和内皮细胞在单核细胞定殖肝脏巨噬细胞龛时赋予其库普弗细胞特征。
Immunity. 2019 Oct 15;51(4):638-654.e9. doi: 10.1016/j.immuni.2019.08.017. Epub 2019 Sep 24.
6
Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner.脂联巨噬细胞以 Trem2 依赖的方式控制代谢稳态。
Cell. 2019 Jul 25;178(3):686-698.e14. doi: 10.1016/j.cell.2019.05.054. Epub 2019 Jun 27.
7
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.一项关于西尼利尤单抗治疗伴有纤维化的非酒精性脂肪性肝炎的随机、安慰剂对照试验。
Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.
8
Macrophage heterogeneity in liver injury and fibrosis.肝损伤和肝纤维化中的巨噬细胞异质性。
J Hepatol. 2014 May;60(5):1090-6. doi: 10.1016/j.jhep.2013.12.025. Epub 2014 Jan 8.
Zotero 插件